Abstract Background: Hepatocelluar carcinoma (HCC) is a common cancer worldwide as well as in Egypt with hepatitis B and C, alcohol and aflatoxins being the commonest risk factors. Tamoxifen was initially reported to confer a marginal survival benefit in advanced HCC. However, later reports declined any benefit. Objective: To study the impact of tamoxifen on overall survival (OS) compared to best supportive care (BSC) in Egyptian patients with advanced HCC. Methods: This retrospective matched-cohort study was conducted at Tanta Cancer Center (TCC), Egypt where 116 advanced HCC cases treated with tamoxifen were compared to TNM stage and Child-Pugh class matched 116 HCC cases who received BSC. Results: The median OS in the tamoxifen group was 9.3 months (95% confidence interval [CI], 6.7-11.9 months) compared to 8.7 months (95%CI, 6.8-10.6) in the BSC group (p = 0.758). With univariate analyses, it was shown that absence of fatigue, Child-Pugh class A, single tumors, less advanced tumors (T2), and absence of metastases (M0), had significantly better OS than their counterparts. Multivariate analysis showed that absence of fatigue, Child-Pugh class A and T2 tumors were independent prognostic factors affecting OS. Tamoxifen produced partial response and 
Introduction
Hepatocelluar carcinoma (HCC) is the most common form of primary liver cancer [1] . Worldwide, liver cancer is the fifth and seventh most common cancer in men and women with 0.5 and 0.25 million new cases per year representing 7.9% and 6.5% of the total cancers in males and females, respectively. Most of HCC burden lies in developing countries. The regions of high incidence include Eastern and SouthEastern Asia, Middle and Western Africa. Worldwide, it is the third most common cause of cancer death with mortality to incidence ratio of 0.93 [2] . In Egypt, liver cancer ranks fourth among all cancers representing 8% of total cancers in both sexes. It is the second cause of cancer mortality representing 10.5% of cancer deaths [2] .
Risk factors for HCC are numerous and include hepatitis B and C infections (HBV and HCV), cirrhosis, aflatoxins, alcohol, smoking and male gender [3] . These risk factors vary among countries, but chronic infections with HBV and HCV are the most important precursors for HCC development on a global scale. Together, HBV and HCV infections account for over 80% of HCC cases worldwide [4] . In Egypt, HCV is the main risk factor for HCC where 71% of HCC cases are positive for anti-HCV antibodies [5] .
HCC has many treatment options. Surgery through resection or transplantation provides the best results in well-selected candidates. If surgery is precluded, local nonsurgical therapies like percutaneous ethanol injection or radiofrequency thermal ablation can be used. Chemoembolization provides modest survival advantage in patients with well-preserved liver function (Child-Pugh class A) and multi-nodular asymptomatic tumors without vascular invasion [6] . Sorafenib, an oral multi-kinase inhibitor, is the only systemic therapy that showed a clear survival benefit in advanced HCC [7] . Systemic chemotherapy, immunotherapy, or anti-androgens did not show survival benefit [6] .
Epidemiological studies in humans suggest that long-term use of oral contraceptives and anabolic androgenic steroids can induce both benign and malignant hepatocellular tumors [8] . Expression of sex hormone receptors, including estrogen receptors (ER), can be detected in variable proportions of HCC that range between 14% and 52% [9] . Earlier reviews showed that the use of tamoxifen conferred a marginal survival benefit [10, 11] . A large randomized controlled trial [12] as well as two reviews [13, 14] did not show survival benefit with tamoxifen use.
The aim of this study is to report the outcome of advanced HCC patients with the use of tamoxifen and to compare that with an equal number of Child-Pugh class and TNM stage-matched patients who received best supportive care (BSC) at the same treating center and during the same time interval.
Methods
This retrospective matched-cohort study was conducted at Tanta Cancer Center (TCC), Ministry of Health, Gharbiah Governorate, Egypt. TCC is the largest cancer center in its governorate and serves 4.2 million people constituting 5.7% of the Egyptian population. Through TCC database, 116 cases with advanced HCC and treated with tamoxifen 20 mg PO QD were identified between the years 2003 and 2006 (Tamoxifen group). Patients were considered eligible for tamoxifen if they were ineligible for surgery, radiofrequency, ethanol injection or trans-arterial chemoembolization. Patients who received other systemic therapies (e.g. chemotherapy) or had an expected survival of less than three months were excluded. Through the same database, we identified 116 advanced HCC patients who received no specific treatment and were matched with the tamoxifen group for both Child-Pugh class and TNM stage (BSC group).
The following data were collected from the medical records: age, sex, residence, occupation, history of hepatitis, smoking, date of diagnosis, presence of cirrhosis, clinical presentation, laboratory results (bilirubin, albumin, international normalized ration (INR), alpha-fetoprotein (AFP)), Child-Pugh class, site, size, number and stage of the primary tumor (T), regional lymph node involvement (N), presence and site of metastases (M), histological grade, treatments (tamoxifen vs. BSC), date of therapy start and end, best overall response, date of progression and date and state of last contact.
The primary endpoint was overall survival (OS). Secondary endpoints were progression free survival (PFS), response rate (RR) and the impact of different clinico-pathological characteristics as well as treatment on OS and PFS. OS was defined as the time (in months) from diagnosis to death. PFS was defined as the time (in months) from start of therapy until progression or death. Response was evaluated according to WHO response criteria [15] .
The study was carried out in compliance with the Helsinki Declaration and was approved by the Institutional Review board of Egyptian National Cancer Institute.
Statistical analyses
Data were analyzed using IBM SPSSÒ Advanced Statistics version 20.0 (SPSS Inc., Chicago, IL). The two treatment groups were matched regarding Child-Pugh class and TNM stage. McNemar test (McNemar-Bowker Test) was used to examine the relation between qualitative variables. For quantitative data, comparison between the two matched groups was done using paired t-test or Wilcoxon signed-ranks test. Survival analysis was done using Kaplan-Meier method and comparison between two survival curves was done using logrank test. Multivariate analysis was done using Cox-regression analysis with forward conditional method for the significant factors affecting survival on univariate analysis. Odds ratio (OR) and its 95% confidence interval (CI) were used for risk estimation. A p-value 6 0.05 was considered significant.
Results
In the two studied groups, Child-Pugh class A and B were encountered in 29.3% and 70.7% of cases and TNM stages II, III and IV were encountered in 6.3%, 75.7% and 18% of cases, respectively. Both groups were largely comparable regarding clinical and pathological characteristics (Table 1) . Patients in both groups were diagnosed in their late fifties, predominately males, rural inhabitants and smokers. Most patients in both groups presented with single tumors, involving the right lobe, of a median largest diameter of 6.5 cm, and with infrequent extra-hepatic extension. Nevertheless, more patients in the Tamoxifen group than the BSC group had viral hepatitis (24.1% vs. 8.6%, p = 0.002), elevated AFP (median, 500 vs. 218 ng/mL, p = 0.001), and tumors 65 cm (35.3% vs. 22.4%, p = 0.036). Abdominal pain, fatigue, ascites and abdominal distension were the most common presentations (Fig. 1) . Fatigue was more common in the tamoxifen group (91% vs. 82%; p = 0.052) and distension was more common in the BSC group (42% vs. 54%; p = 0.034). Almost 63% of cases were diagnosed histologically, 11% showed a classic triphasic CT picture of HCC (arterial enhancement and rapid venous washout), and the rest of cases (26%) were diagnosed based on elevated AFP together with the presence of cirrhosis and hepatic focal lesions in liver ultrasound. In both groups, low-grade tumors (grade 1 or 2) were more common than high-grade tumors (grade 3 or 4). In patients presenting with metastatic disease, bone was the most common site of metastases in both groups. The median follow up period was 15.3 months (95%CI, 10.8-19.8). At the last documented visit, 139 patients were dead; 73 in the BSC group and 66 in the tamoxifen group. The median OS in the tamoxifen group was 9.3 months (95%CI, 6.7-11.9) compared to 8.7 months (95%CI, 6.8-10.6) in the BSC group (p = 0.758; Fig. 2 ). This is translated into a hazard ratio of death in the tamoxifen arm of 0.95 (95%CI, 68-1.3). The 12-month OS rate in the tamoxifen group was 41.2% compared to 40.7% in the BSC group.
The impact of various factors on OS was explored ( Table 2) . Absence of fatigue, Child-Pugh class A, single lesions, T2 tumors, absence of metastases (M0), all had significantly better OS than their counterparts. Survival of patients who received tamoxifen was not significantly different from that of patients who received BSC only. Multivariate analysis showed that absence of fatigue, Child-Pugh class A and T2 tumors were independent prognostic factors affecting OS (Table 3) .
In the tamoxifen group, the median duration of tamoxifen use was 4 months with an inter-quartile range (IQR) of 3-8 months. Regarding the best overall response, only one patient achieved a documented partial response (Table 4) . The rest of patients were assessed on clinical basis with 16% achieving clinical stabilization and 53% showing primary clinical progression (Table 4) . Thirty-four patients (29%) were non-evaluable for response. The drug was generally tolerable with clinical deterioration (e.g. deepening jaundice, increasing ascites, elevated transaminases, worsening pains) being the most common reason for drug withdrawal.
In the tamoxifen group, the median PFS was 7.2 months (95%CI, 5.2-9.5; Fig. 3 ). The impacts on PFS of factors like age, sex, residence, occupation, hepatitis, smoking, fatigue, Child-Pugh class, number of lesions, AFP and TNM stage were assessed. Only absence of fatigue and Child-Pugh class A had significantly higher PFS than the presence of fatigue and Child-Pugh class B (p = 0.026 and <0.001, respectively).
Discussion
HCC is a major health problem in Egypt ranking as the second and sixth cancer in males and females representing 11.9% and 3.9% of all cancers, respectively. It is the second and sixth cause of cancer mortality representing 14.4% and 5.7% in males and females, respectively [2] . Many patients present with advanced disease beyond curative surgery and effective local and regional therapies [16] .
Despite not a prospective randomized controlled trial (RCT), our study included a good number of patients with advanced HCC distributed equally between those who received tamoxifen and those who received BSC. They were derived from the same treating center and during the same periods. This minimized the effects of markedly different treatment policies between the two groups. They were matched regarding tumor stage and Child-Pugh class, being very important prognostic factors in advanced HCC. Our study reflects the usual practice outside the setting of controlled clinical trials.
Patients included in this study are similar to patients with HCC reported in large Egyptian series [16, 17] . The median age, predominance of males and rural inhabitance, farmers' representation, the prevalence of HCV, HBV and combined HBV and infection, clinical presentations, predominance of tumors larger than 5 cm in diameter, lobar sites, predominance of single lesions, were similar in the two studies. However, our study included more Child-Pugh B patients (71%) than the mentioned study (37%) and this is explained by the fact that our patients were largely advanced cases that were ineligible for any surgical or other local and loco-regional interventions compared to the mentioned study that included 60% of patients who received surgery or other local and loco-regional treatments. Thus, we believe that our HCC patients are representative of Egyptian patients with advanced HCC.
Patients included in the current study largely resembled those included in two large prospective randomized trials that tested tamoxifen against BSC or no specific therapy in advanced HCC patients [12, 18] . However, the median age was 6-10 years lower in our patients compared to Italian and French patients. This reflects the lower life expectancy in Egyptians (69 years in males and 73 years in females) compared to Italian (77.9 years in males and 84 years in females) and French people (78 years in males and 85 years in females) [19] . It may also reflect earlier age at exposure to risk factors including HCV, HBV, aflatoxins and insecticides [1] . Similar to an Italian study [12] , most of our patients had viral hepatitis etiology mainly HCV. This is different from the French study where alcoholic cirrhosis was the predominant risk factor [18] . All patients in the current study had evidence of cirrhosis compared to 87%-92% in the mentioned studies. None of our patients had Child-Pugh class C compared to 1%-15% in the mentioned studies. None of the patients in the current study received surgery, local or regional therapies compared to 47% and 15% in the Italian and French studies, respectively [12, 18] . Similar to many RCTs [12, 18, [20] [21] [22] [23] [24] and meta-analyses [12] [13] [14] , we showed that tamoxifen did not confer any OS benefit in advanced HCC. However, the earlier claims of an OS benefit with the use of tamoxifen suggested by some RCTs [25, 26] and earlier meta-analyses [10, 11] were criticized. These RCTs [23, 25, 26] were mentioned to be of a low quality due to methodological bias and random error of small sized trials and thus they distorted earlier meta-analyses [10, 11] . When high quality RCTs [12, 21, 22, 27] were included in the later metaanalyses [12] [13] [14] , the survival benefit was no longer seen.
The median OS of tamoxifen and BSC groups in our study (9.3 and 8.7 months, respectively) is lower than that of the CLIP trial (15 and 16 months, respectively) [12] . In addition, the one-year survival in the current study was lower (41.2% vs. 56% for the tamoxifen and 40.7% vs. 57% for the control group). This can be explained by the higher percentage of patients eligible for concurrent effective loco-regional therapies in the CLIP trial (47%) compared to the current study (0%). When patients receiving loco-regional therapies in the CLIP trial were excluded, the median survival dropped significantly (6 and 5 months for tamoxifen and controls, respectively). Similarly, the 1-year OS rate dropped to be 30% in the tamoxifen and 35% in the control groups. These figures are even lower than the corresponding figures in our current study. This may be explained by the inclusion of Child-Pugh class C (12.6%) in the CLIP trial compared to none in the current study.
The figures for median OS and 1-year survival rates in the current study are higher than the French RCT trial [18] . Patients in the French study were almost 10 years older than those in the present study with alcoholic cirrhosis in their majority compared to none in the current study. In addition, that study included some patients with Child-Pugh class C patients who were not represented in our study. Moreover, patients included in our study should have fulfilled an expected life expectancy more than 3 months like the CLIP study [12] . This issue was not mentioned in the French study.
Similar to the French study [18] , univariate analysis in the current study showed that Child-Pugh class, tumor size and numbers, presence of metastases were predictors of survival. Also, we showed that fatigue was associated with survival both in univariate and multivariate analyses in addition to ChildPugh class.
Similar to other investigators [21, 23, 28, 29] , we showed that tumor responses to tamoxifen were very rare. The lack of tamoxifen efficacy could be due to either low expression of wild-type ER (wER) [12] or to expression of mutated variants (vER) that are inhibited by tamoxifen [30] .
The impact of ER expression on benefit from tamoxifen was studied as a secondary analysis of a RCT and the results were negative [23] . However, this approach was criticized. Patients were not prospectively selected or stratified according to qualitative or quantitative hormonal receptors' expression. Immune-histochemical determinations were performed only on a subgroup of 66/119 patients with adequate tissue specimen. The prognosis of the patients enrolled in that study was dismal, with a median survival of 44 days in the tamoxifen compared to 41 days in the control group [9] .
Tailoring anti-hormonal therapy according to the type of ER was tried in a small trial where wER patients were treated with tamoxifen and vER patients received megesterol acetate with good responses in the tamoxifen group [31] . However, these preliminary results still lack confirmation in adequately powered and designed RCTs that prospectively select patients with wild-type ER and randomize them to receive tamoxifen or no treatment. Also, adequately powered prospective phase III trials assessing the efficacy of tamoxifen in patients selected or stratified (prospectively or retrospectively) for ER expression have never been conducted [9] . Increasing the dose of tamoxifen did not prove to provide a better survival but rather was more detrimental [14, 24] . There were no significant differences between tamoxifen and BSC arms within subgroups defined by prognostic variables such as stage, AFP level, portal vein thrombosis, number of liver lesions, extent of liver involvement, the preceding local or regional therapies [12] and gender [14] . Thus, the use of tamoxifen in advanced HCC is discouraged particularly with the availability of newly approved drugs like Sorafenib [7] .
In conclusion, this matched-cohort study confirms the evidence from previous RCTs and shows the lack of survival benefit with the use of tamoxifen in advanced HCC. Further use of this drug is discouraged in these patients. Research to find more therapeutic targets and effective targeting agents is eagerly needed in this disease with its grave prognosis.
